The Food and Drug Administration (FDA) asked a federal court on Jan. 27 to pause a lawsuit that Louisiana brought to reverse the Biden administration’s deregulation of the abortion pill mifepristone.
The agency asked a federal court to “stay all proceedings in the matter” while it studies its policy permitting mifepristone to be mailed to patients without an in-person visit to a doctor.
